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Abstract
Purpose of Review—To describe the mechanisms and consequences of both microbial 
translocation and microbial dysbiosis in HIV infection.
Recent Findings—Microbes in HIV are likely playing a large role in contributing to HIV 
pathogenesis, morbidities and mortality. Two major disruptions to microbial systems in HIV 
infection include microbial translocation and microbiome dysbiosis. Microbial translocation 
occurs when the bacteria (or bacterial products) that should be in the lumen of the intestine 
translocate across the tight epithelial barrier into systemic circulation, where they contribute to 
inflammation and pathogenesis. This is associated with poorer health outcomes in HIV infected 
individuals. In addition, microbial populations in the GI tract are also altered after HIV infection, 
resulting in microbiome dysbiosis, which further exacerbates microbial translocation, epithelial 
barrier disruption, inflammation, and mucosal immune functioning.
Summary—Altered microbial regulation in HIV infection can lead to poor health outcomes, and 
understanding the mechanisms underlying microbial dysbiosis and translocation may result in 
novel pathways for therapeutic interventions.
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Immune activation is a hallmark of HIV infection and is stongly associated with AIDS and 
non-AIDS morbidity and mortality. There are several causes of immune activation in HIV 
infected individuals, however mucosal dysfunction is a major factor contributing to 
persistent inflammation and immunological dysfunction. Mucosal dysfunction in HIV 
infection is characterized by drastic immunological alterations, breaches in the epithelial 
barrier, translocation of microbial products into circulation, and microbiome dysbiosis 
[1,2**]. Thus the mucosal barrier of the gastrointestinal (GI) tract is a central component of 
HIV. As the GI tract contains the largest source of CD4+ T cells it is not surprising to be a 
primary site of ongoing viral replication [3,4]. However, despite antiretroviral therapy 
(ART) that restricts virus replication, complete restoration of barrier function does not occur 
and mucosal immune dysfunction persists [5,6].
The proper functioning of the mucosal barrier relies on protein structures that maintain 
epithelial integrity including tight junctions, adherens junctions, or desmosomes. These 
structures adhere cells to one another [7], which seals the paracellular space between 
epithelial cells and forms branching networks of strands that help form intact epithelial 
sheets [8]. Although the complete understanding and the etiology of epithelial disruption 
during HIV infection remains unclear, it is known that these tight junctions are breached 
during HIV infection [6], which has been linked to many immunological influences [9**]. 
For example, homeostatic T cell subsets are lost very early in infection, including Th17 
cells, which are crucial in responding to bacterial antigens [10*,11*]. Indeed, Th17 cells in 
HIV infection are thought to aid in maintainence of the epithelial barrier by amplifying 
signals of microbial translocation [12]. Also, neutrophils, which are crucial in the immune 
response to bacterial and fungal pathogens [13], infiltrate into the GI tract in both HIV and 
the simian immunodeficiency virus (SIV) model of infection [2,14]. This coincides with 
damage to the epithelial barrier and microbial translocation, suggesting that neutrophils are 
responding to translocation of bacterial products but are unable to contribute to their 
containment, but could be releasing inflammatory factors that contribute to barrier damage 
[15*]. However, their contribution to mucosal dysfunction in the GI tissue is unknown [2**,
14]. Many other effects on local immune cell milieu, epithelial cell responses, virus-cell 
interactions [16], altered molecular events [17], enhanced proinflammatory soluble products 
[18,19], and altered microbial regulation have been observed which suggest a multifacotral 
process [1,20]. While acknowledging there are many immunological contributions to this 
disruption, this review will focus on the contributing roles of microbial dysbiosis and 
translocation HIV-related inflammation.
Microbial Translocation in HIV infection
Microbial translocation (MT) is defined as the movement of microbial products from the gut 
mucosa into circulation. Though recognized in other fields, MT in the context of HIV was 
first characterized only 10 years ago [21], but the finding has since been replicated in many 
cohorts and is now accepted as a general phenomenon in HIV. In retrospect, MT in HIV 
should not be surprising, given that HIV is a gut tropic infection and a site of major and 
irreversible damage regardless of how infection is acquired [22,23]. In addition the gut 
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represents one of the body's largest and most influential microbiomes, exerting an impact on 
a diverse range of human health and immunological conditions [24,25].
MT has been found to be a major driver of morbidity and mortality in HIV infection, likely 
due to the persistent inflammation it induces and sustains [26-28]. Importantly, the 
associations between microbial translocation and disease progression and mortality are 
independent of whether the HIV-infected individual is virally suppressed with ART [29]. A 
commonly identified translocating microbial product is lipopolysaccharide (LPS) from the 
surface of Gram-negative bacteria [21]. Several studies have demonstrated direct 
correlations between plasma LPS levels in HIV-infected individuals residual viremia, 
cellular activation including CD38+HLA-DR+ CD8+ T cells and activation of monocytes, 
interferon responsive genes such as MxA, and proinflammatory cytokines including IFN-α, 
IL-6, TNFα [21,23,30-34]. In addition, LPS levels and/or bacterial DNA levels directly 
correlate with other markers of microbial translocation and innate immune activation such as 
soluble CD14 (sCD14; released by monocytes in response to bacterial stimulation), LPS-
binding protein (LBP) and endotoxin. While it is unclear how much inflammation during 
HIV infection is directly attributed to microbial translocation given the many inflammatory 
mechanisms which occur during HIV infection (including virus replication, opportunistic 
infections, etc.), studies in the absence of HIV demonstrate relationships between microbial 
translocation and inflammation. In idiopathic CD4 lymphocytopenia (ICL), LPS is elevated 
and associated with proliferating CD4+ T cells [35], and colon LPS levels in uninfected 
pigtail macaques correlate with interferon responsive gene MxA in the GI tract [36], 
demonstrating that microbial products can directly stimulate inflammatory responses.
Microbial translocation occurs early in infection, and in SIV models has been demonstrated 
to begin mainly in the post-peak viremia phase, or days 14-28 post-SIV infection [14]. 
However, prior to infection in the macaque SIV model, the extent of epithelial breaches and 
MT predicts the kinetics of progression to AIDS [33]. Additionaly, epithelial damage and 
local inflammation predicts mortality in HIV infection [2**,37**]. Indeed, a major 
mechanism which drives MT is focal breaches that occur to the epithelial barrier of the GI 
tract, which physically allows microbial products to translocate [14,36], however it is 
unclear what induces these breaches. One potential mechanism underlying damage to the 
epithelial barrier is alterations in the microbial communities of the GI tract. In HIV 
infection, there is an increased abundance of epithelial-adherent bacteria of the 
Proteobacteria family [38], and interestingly, it is this increased Proteobacteria that is found 
to predominantly translocate in SIV infection [39**]. This suggests that interactions 
between bacteria associated with the mucosa and the epithelium may contribute to MT. 
However, the relative contribution of various host and microbial factors to barrier damage 
are not well defined and studies examining these processes promise to provide novel targets 
for therapeutics designed to restore GI barrier function.
Microbial dysbiosis in HIV infection
Microorganisms associated with the GI lumen and mucosa are mostly bacteria but also 
include Archaea, Fungi, other eukaryotes such as helminthes, and viruses, many of which 
are bacteriophages [40-43]. It has become exceedingly clear that GI resident microbes and 
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their associated metabolites are required to maintain proper function of the immune system 
and general health [40]. Perturbation of these microbial communities can have dramatic 
impacts on the health of the host and recent studies have demonstrated that shifts in the 
composition and function of the GI microbiome are associated with many disease states 
including HIV [38,44**,45].
HIV-induced alterations to the gut microbiota are most commonly characterized by overall 
decreased diversity [46], with reduced abundances of the genus Bacteroides and increased 
abundances of the genus Prevotella [38,44-45, 46**, 47]. Bacteria from these two genera are 
known to be important drivers of gut ecology and function [48]. Thus, shifts in the 
abundances of these bacteria can have major consequences for the gut microbiome and host. 
Indeed, altered abundances of Bacteroides and Prevotella have been implicated in a number 
of disease states, such as inflammatory bowel diseases (IBD) [49-52]. Table 1 shows 
different genera of bacteria found to be altered in HIV infection and possible roles for these 
bacteria in the context of the diesease.
Loss of bacteria from the gut may reduce the ability of HIV-infected individuals to manage 
gastrointestinal inflammation, and may result in altered T cell subsets shown in HIV 
infection. For example, in murine models, polysaccharide A (PSA) produced by Bacteroides 
fragilis has been shown to increase the expression of the anti-inflammatory cytokine IL-10 
and increase populations of memory CD4+ T cells [67]. Additionally, Bacteroides are 
typically associated with the gut microbiota of individuals that consume a diet rich in 
animal-derived fats and glycans [74] and reduced abundances of these bacteria may lead to a 
diet-microbiome mismatch in HIV-infected individuals, which can manifest as metabolic 
disease [75].
Other bacterial genera that are reduced in abundance in HIV infection are Lactobacillus, 
Bifidobacterium, Coprococcus, Eubacterium, Blautia, and Ruminococcus. Genera enriched 
in the gut microbiome of HIV-infected individuals include Pesudomonas, Acinetobacter, 
Campylobacter, Escherichia, and Desulfovibrio [38,44-47,54,76**]. Lactobacillus spp. and 
Bifidobacterium spp. are generally regarded as beneficial, especially in the context of 
mucosal immunity and administration of probiotic supplements containing these bacteria 
have been found to be highly beneficial in the context of GI disease and inflammation 
[77-80]. These bacteria are also known to provide B and K vitamins to the host which are 
necessary for a variety of metabolic processes [71]. Coprococcus spp., Eubacterium spp., 
Blautia spp., and Ruminococcus spp. are usually commensal bacteria that are rarely 
implicated in intestinal infections and ferment dietary polysaccharides to form short chain 
fatty acids (SCFAs) such as acetate and butyrate, which are important energy sources for 
intestinal epithelial cells [57,72,81]. The genera Pseudomonas, Acinetobacter, 
Campylobacter, and Escherichia include a variety of opportunistic pathogens [56,60,61,82] 
while Desulfovibrio spp. produce toxic hydrogen sulfide and are closely associated with the 
mucosa [83,84]. Expansion of these bacteria has been implicated in the pathogenesis of 
other inflammatory bowel diseases [85]. Thus, HIV-induced dysbiosis appears to be 
characterized by decreased abundances of bacteria that are generally regarded as 
commensal, fermentative, or protective accompanied by an expansion of bacteria that are 
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potentially inflammatory or pathogenic, which agrees with the general phenotype of 
mucosal inflammation in HIV infection.
In the SIV model, Handley et al. showed that an overall decrease in bacterial populations 
and an increase in enteric viruses was linked to GI pathology [86]. Interestingly, the authors 
of this study did not detect significant dysbiosis of the bacterial component of the 
microbiome. However these studies were performed on fecal samples, which do not exhibit 
dysbiosis as clearly as tissue samples in HIV or SIV infection. These authors also 
demonstrated an increase in enteric viruses in viremic macaques, including altered 
bacteriophages, which could be a potential mechanism underlying altered microbiome in 
HIV infection, and should be researched further. Another recent study demonstrated shifts in 
the oral fungal microbiota in ART-treated, HIV-infected individuals characterized by 
increased Candida colonization, which may cause infection [87**]. Studies examining 
potential dysbiosis of fungal or Archaeal communities in the gut of HIV-infected individuals 
are lacking and warrant investigation. Further, given the unclear mechanisms underlying 
dysbiosis, the interactions between bacteria, viruses, fungi and Archaea should be better 
elucidated in order to develop a complete understanding of the nature of HIV-induced 
dysbiosis.
Microbial dysbiosis in immunity and inflammation
The alterations to the microbiome in HIV infection have also been demonstrated to result in 
direct effects on immunity and increased inflammation (summarized in Figure 1). Vujkovic-
Cvijin et al. demonstrated that enrichment of Proteobacteria and loss of Bacteroides in HIV 
infection results in increased adherent bacteria to the mucosal epithelium, which could be a 
mechanism for barrier damage, although this has not been directly demonstrated [38]. In 
addition, the authors of this study found that dysbiosis of the microbiome was associated 
with increased gut and peripheral T cell activation, and plasma inflammatory soluble factors, 
which have independently been found to be associated with HIV pathogenesis [38,88,89]. 
Furthermore, dysbiosis was associated with an increased Kynurenine:Tryptophan ratio 
(Kyn:Trp) and increased indoleamine-2,3-dioxygenase (IDO) activity, which were 
previously demonstrated to be associated with loss of mucosal IL-17 producing cells [90], 
also a pathogenic consequence of HIV infection [91-93].
Dillon et al. recently demonstrated that HIV-altered mucosal bacteria (HAMBs) are 
associated with inflammatory responses from immune cells. Here the authors found that 
increased abundance of Prevotella in HIV-infected individuals was associated with 
increased mucosal T cell and dendritic cell (DC) activation [44]. Furthermore, the co-
culturing of HAMBs with colonic lamina propria mononuclear cells, including Prevotella 
copri and Prevotella stercore, directly stimulated activation of CD1c+ DCs, compared to 
bacteria lost in HIV including Rumminococcus bromii [94**]. This may affect HIV 
pathogenesis given that the authors also demonstrated DC activation in mucosal tissues was 
associated with increased mucosal viral load, increased mucosal and systemic T cell 
activation, and increased plasma and mucosal cytokine production, including several 
cytokines associated with mortality in HIV infection IL-6, TNFα, IL-10, IL-1β, and IFNγ 
[94**]. Thus, there is a clear relationship between microbial dysbiosis on immunity and 
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inflammation in HIV infection, and preventing or reversing this altered GI microbiome in 
HIV infection may result in beneficial effects on immunity. However, whether altered 
immunity after HIV infection drives dsybiosis or vice versa is unclear, and cause and effect 
of microbe dysregulation relative to immune dysfunction needs to be clarified.
Another role of the microbiome in HIV that is not as clear is the ability of the microbiome to 
drive IgA responses. It is well established that secretory IgA in the lamina propria is 
essential for proper management and containment of intestinal microbiota [95]. Indeed, IgA 
in mucosal tissues can act to protect from pathogens, block microbe-epithelium interactions, 
clear microbes from lamina propria if translocated, and can itself act to shape the microbiota 
[95-97]. Given the loss of CD4+ T cells, and specifically T follicular helper (Tfh) cells 
which induce class switching of B cells, during HIV infection, a potential mechanism 
underlying altered microbiome could be loss of IgA control in mucosa, but these 
mechanisms have not been clearly defined. Of interest, recent studies have demonstrated 
that there is a dual specificity of IgA for the microbiome and HIV [98**,99]. Thus, altered 
IgA responses in the presence of HIV infection could be an underlying mechanism of 
microbiome dysbiosis or lack of immune control of the microbiota. Interestingly, a link 
between IgA and neutrophil responses has recently been demonstrated whereby neutrophils 
negatively regulated mucosal IgA after vaccination [100**]. Given the accumulation of 
neutrophils during HIV infection the interactions bewtween neutrophils and IgA depletion in 
this context may be a novel avenue of exploration..
Therapeutic approaches to improve microbiome and microbial 
translocation in HIV infection
Novel therapies to restore the microbiome and repair damage to the GI epithelial barrier can 
improve mucosal function and may reduce morbidity and mortality in ART-treated HIV-
infected individuals. Oral administration of beneficial microbes in the form of probiotic 
supplements have attracted attention as a method to enhance mucosal function by increasing 
mucus production, preventing apoptosis, or stabilizing tight junctions [101]. In a recent 
study, intake of a probiotic containing several Lactobacillus, Bifidobacterium, and 
Streptococcus spp. significantly reduced CD4+ and CD8+ T cell activation and plasma 
concentrations of high-sensitivity C-reactive protein, a biomarker associated with 
cardiovascular disease risk, in ART treated HIV-infected adults [102**]. Interestingly, these 
patients also reported fewer episodes of diarrhea and constipation. However, plasma 
concentrations of sCD14, a biomarker of MT, did not decrease after sustained probiotic 
intake [102**]. Another study demonstrated that intake of a probiotic yeast, Saccharomyces 
boulardii, reduced plasma concentrations of LBP and IL-6 in ART-treated HIV-infected 
individuals [103*]. Similarly, intake of prebiotic oligosaccharides significantly increased 
populations of beneficial Bifidobacterium spp., reduced plasma concentrations of sCD14, 
and reduced CD4+ T cell activation in a cohort of untreated HIV-infected individuals [104]. 
Probiotic therapy in SIV-infected non-human primates treated with ART results in multiple 
benefits to mucosal immunity including increased mucosal CD4+ T cell frequency and 
functionality, which was attributed to decreased fibrosis in the GI tract [70]. In addition, the 
authors observed improved functionality of antigen presenting cells (APCs) without overt 
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DC activation, suggesting that innate immunity can also be enhanced by probiotic 
supplementation [70]. In a follow up study, ART-treated SIV-infected macaques were given 
a combination of probiotics and IL-21, which also improved frequencies of Th17 cells, 
potentially due to an observed decrease in Kyn:Trp ratios and decreased IDO activity in 
plasma [105**].
The drug sevelamer, which sequesters bacterial LPS, has been shown to reduce plasma 
concentrations of LPS and sCD14 while also decreasing immune activation when 
administered to macaques during acute SIV infection [106*]. Administration of sevelamer 
did not reduce plasma LPS concentrations in patients in the chronic stage of HIV infection, 
but did produce potential cardiovascular benefits [107*]. Similarly, treatment of HIV-
infected individuals with hyperimmue bovine colostrum containing anti-LPS antibodies did 
not reduce plasma LPS concentrations [108]. In SIV-infected macaques, blockade of the 
immune inhibitory receptor programmed death-1 (PD-1), which plays a critical role in 
determining the functionality of HIV-specific T cells, improved gut barrier function by 
increasing expression of tight junction proteins and reduced plasma LPS concentrations. 
Furthermore, PD-1 blockade enhanced immune responses against potentially pathogenic 
bacteria [109]. Together, these studies demonstrate that therapies designed to restore the 
structure and function of the microbiome and reduce microbial translocation can be effective 
for reducing inflammation in ART-treated HIV-infected individuals. However, further 
studies are needed to properly assess the efficacy of these approaches and need for 
combinational approaches, and whether restoration of the GI tract is even possible after the 
extensive damage that HIV induces in mucosal tissues rapidly after infection.
Conclusion
It is clear that HIV infection results in damage to the GI mucosa and epithelium leading to 
translocation of microbes and microbial products into the lamina propria and systemic 
circulation and that these events are accompanied by dysbiosis of the GI-resident microbes. 
However, whether this dysbiosis is a cause or a symptom of immune dysregulation in HIV 
remains unclear. The intestinal microbiome is heavily regulated by the innate and adaptive 
arms of the immune system and the microbiota contribute to its maintainance [40]. 
Persistent activation of the immune system may lead to an inability of the host to properly 
regulate the microbiome. This, in turn, may result in microbial dysbiosis and outgrowth of 
potentially pathogenic bacteria, which creates an inflammatory cycle. Thus, in order to 
identify novel targets for therapeutic intervention, it is imperative to better understand the 
interplay between microbial community changes and mucosal dysfunction in HIV infection.
Acknowledgments
Financial support and sponsorship: Personnel time and support provided by University of Washington (AZ, NK), 
CAPRISA (LM) and University of Manitoba (AB).
References
1. Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for 
transmission and pathogenesis. Curr Opin Immunol. 2015; 36:22–30. [PubMed: 26151777] 
Zevin et al. Page 7













2**. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, 
McCune JM, Hunt PW. Gut epithelial barrier and systemic inflammation during chronic HIV 
infection. AIDS. 2015; 29:43–51. • The authors find that in ART-treated HIV infected 
individuals, there is increased neutrophil accumulation and epithelial apoptosis in the GI tract 
which may contribute to GI immunological dysfunction and immune activation in HIV. 
[PubMed: 25387317] 
3. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, 
Johnson RP, Desrosiers RC, Lackner AA. Gastrointestinal tract as a major site of CD4+ T cell 
depletion and viral replication in SIV infection. Science. 1998; 280:427–431. [PubMed: 9545219] 
4. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss 
of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005; 434:1093–
1097. [PubMed: 15793563] 
5. Macal M, Sankaran S, Chun TW, Reay E, Flamm J, Prindiville TJ, Dandekar S. Effective CD4+ T-
cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with 
enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 2008; 
1:475–488. [PubMed: 19079215] 
6. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal 
Immunol. 2008; 1:23–30. [PubMed: 19079157] 
7. Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol. 
2007; 127:2525–2532. [PubMed: 17934504] 
8. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009; 
9:799–809. [PubMed: 19855405] 
9**. Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, Abou M, Westmacott GR, 
McCorrister S, Kwatampora J, et al. Increased levels of inflammatory cytokines in the female 
reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, 
and an influx of HIV-susceptible target cells. Mucosal Immunol. 2015 • The authors find 
increased inflammatory proteins, including neutrophil proteases, in mucosal barriers is associated 
with increased HIV acquisition. 
10*. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler 
NG, Sukhumvittaya S, Marovich M, et al. Initiation of ART during early acute HIV infection 
preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 
2014; 10:e1004543. • The authors find that Th17 cells in the GI tract are lost early in HIV 
infection and associated with mucosal and systemic inflammation; Th17 could be preserved only 
by early (Fiebig I/II) initiation of ART. [PubMed: 25503054] 
11*. McKinnon LR, Nyanga B, Kim CJ, Izulla P, Kwatampora J, Kimani M, Shahabi K, Mugo N, 
Smith JS, Anzala AO, et al. Early HIV-1 infection is associated with reduced frequencies of 
cervical Th17 cells. J Acquir Immune Defic Syndr. 2015; 68:6–12. • The authors found loss of 
CCR6+ CD4+ T cells early in HIV infection in the cervix, association with high levels of 
RANTES and MIP3a in cervicovaginal fluids. [PubMed: 25296095] 
12. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, 
Sankaran S, Paixao TA, Gordon MA, et al. Simian immunodeficiency virus-induced mucosal 
interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 
14:421–428. [PubMed: 18376406] 
13. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006; 
6:173–182. [PubMed: 16498448] 
14. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, 
Oliveira KM, et al. Damaged intestinal epithelial integrity linked to microbial translocation in 
pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010; 6:e1001052. [PubMed: 
20808901] 
15*. Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, Beq S, Lafaye de 
Micheaux S, Yao MD, Ober A, et al. Decreases in colonic and systemic inflammation in chronic 
HIV infection after IL-7 administration. PLoS Pathog. 2014; 10:e1003890. • The authors found 
that that administering IL-7 to HIV-infected individuals with low CD4+ T cell counts improved 
both CD4+ and CD8+ T cells in blood, as well as increased the gut homing marker α4β7. 
[PubMed: 24497828] 
Zevin et al. Page 8













16. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, 
Kaushic C. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing 
microbial translocation. PLoS Pathog. 6:e1000852. [PubMed: 20386714] 
17. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T, Dandekar S. Rapid onset 
of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is 
driven by an imbalance between immune response and mucosal repair and regeneration. J Virol. 
2008; 82:538–545. [PubMed: 17959677] 
18. McGowan I, Radford-Smith G, Jewell DP. Cytokine gene expression in HIV-infected intestinal 
mucosa. AIDS. 1994; 8:1569–1575. [PubMed: 7848593] 
19. Hirao LA, Grishina I, Bourry O, Hu WK, Somrit M, Sankaran-Walters S, Gaulke CA, Fenton AN, 
Li JA, Crawford RW, et al. Early mucosal sensing of SIV infection by paneth cells induces 
IL-1beta production and initiates gut epithelial disruption. PLoS Pathog. 2014; 10:e1004311. 
[PubMed: 25166758] 
20. Poles MA, Fuerst M, McGowan I, Elliott J, Rezaei A, Mark D, Taing P, Anton PA. HIV-related 
diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. Am 
J Gastroenterol. 2001; 96:1831–1837. [PubMed: 11421246] 
21. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, 
Lambotte O, Altmann D, et al. Microbial translocation is a cause of systemic immune activation in 
chronic HIV infection. Nat Med. 2006; 12:1365–1371. [PubMed: 17115046] 
22. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat 
Immunol. 2006; 7:235–239. [PubMed: 16482171] 
23. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV 
disease. Trends Microbiol. 2013; 21:6–13. [PubMed: 23062765] 
24. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome 
and the immune system. Nature. 2011; 474:327–336. [PubMed: 21677749] 
25. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience 
of the human gut microbiota. Nature. 2012; 489:220–230. [PubMed: 22972295] 
26. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, 
Neuhaus J, Nixon D, et al. Inflammatory and coagulation biomarkers and mortality in patients 
with HIV infection. PLoS Med. 2008; 5:e203. [PubMed: 18942885] 
27. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips 
AN. Activation and coagulation biomarkers are independent predictors of the development of 
opportunistic disease in patients with HIV infection. J Infect Dis. 2009; 200:973–983. [PubMed: 
19678756] 
28. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, 
Lewin SR, Emery S, et al. Plasma levels of soluble CD14 independently predict mortality in HIV 
infection. J Infect Dis. 2011; 203:780–790. [PubMed: 21252259] 
29. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, 
Lewin SR, Emery S, et al. Plasma levels of soluble CD14 independently predict mortality in HIV 
infection. J Infect Dis. 2011; 203:780–790. [PubMed: 21252259] 
30. Ancuta P, Kamat A, Kunstman KJ, Kim E-Y, Autissier P, Wurcel A, Zaman T, Stone D, Mefford 
M, Morgello S, et al. Microbial Translocation Is Associated with Increased Monocyte Activation 
and Dementia in AIDS Patients. PLoS ONE. 2008; 3:e2516. [PubMed: 18575590] 
31. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, Alfano M, Poli G, 
Rossouw T. Persistent Microbial Translocation and Immune Activation in HIV-1-Infected South 
Africans Receiving Combination Antiretroviral Therapy. J Infect Dis. 2010 Sep 1.202:723–733. 
[PubMed: 20629534] 
32. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, 
Asher AI, et al. Plasma levels of bacterial DNA correlate with immune activation and the 
magnitude of immune restoration in persons with antiretroviral-Treated HIV infection. J Infect 
Dis. 2009; 199:1177–1185. [PubMed: 19265479] 
33. Canary LA, Vinton CL, Morcock DR, Pierce JB, Estes JD, Brenchley JM, Klatt NR. Rate of AIDS 
progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-
infected pigtail macaques. J Immunol. 2013; 190:2959–2965. [PubMed: 23401593] 
Zevin et al. Page 9













34. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor 
ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One. 2008; 
3:e1915. [PubMed: 18382686] 
35. Lee PI, Ciccone EJ, Read SW, Asher A, Pitts R, Douek DC, Brenchley JM, Sereti I. Evidence for 
translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis. 
2009; 199:1664–1670. [PubMed: 19432548] 
36. Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, Morcock D, McGinty JW, Lifson 
JD, Lafont BA, et al. Compromised gastrointestinal integrity in pigtail macaques is associated with 
increased microbial translocation, immune activation, and IL-17 production in the absence of SIV 
infection. Mucosal Immunol. 2010; 3:387–398. [PubMed: 20357762] 
37**. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, 
Epling L, Martin JN, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation 
Predict Mortality in Treated HIV Infection. J Infect Dis. 2014 • Here the authors find that 
intestinal fatty acid binding protein, zonulin-1, soluble CD14, kynurenine/tryptohpan ratio, 
soluble tumor necrosis factor receptor 1, high-sensitiivty C-reactive protein, and D-dimer levels 
all predicted mortality. 
38**. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez 
RD, Lederman MM, Huang Y, Somsouk M, et al. Dysbiosis of the gut microbiota is associated 
with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013; 5:193ra191. • 
The authors find that dysbiosis of the microbiome in the colon occurs during HIV infection, 
described by increased adherent bacteria, and is associated with increased tryptophan catabolism 
that may underlie immune activation during HIV. 
39**. Klase Z, Ortiz A, Deleage C, Mudd JC, Quinones M, Schwartzman E, Klatt NR, Canary L, Estes 
JD, Brenchley JM. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal 
Immunol. 2015 • The authors find that the bacteria which translocate during SIV infection in 
macaques is predominantly Proteobacteria, which is also assocaited with dysbiosis of the 
microbiome in HIV infection. 
40. Thaiss CA, Levy M, Suez J, Elinav E. The interplay between the innate immune system and the 
microbiota. Curr Opin Immunol. 2014; 26:41–48. [PubMed: 24556399] 
41. Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends Microbiol. 
2014; 22:399–405. [PubMed: 24656964] 
42. Oever JT, Netea MG. The bacteriome-mycobiome interaction and antifungal host defense. Eur J 
Immunol. 2014; 44:3182–3191. [PubMed: 25256886] 
43. Pimentel M, Gunsalus RP, Rao SSC, Zhang H. Methanogens in Human Health and Disease. The 
American Journal of Gastroenterology Supplements. 2012; 1:28–33.
44**. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, Gianella S, Siewe B, Smith DM, 
Landay AL, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with 
mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014; 7:983–994. 
• The authors find that HIV results in dysbiosis and contributes to T cell and dendritic cell 
activation as well as endotoxemia. [PubMed: 24399150] 
45. Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, Knight R, Fontenot AP, 
Palmer BE. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe. 
2013; 14:329–339. [PubMed: 24034618] 
46**. Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C, French A, Demarais P, 
Sun Y, Koenig L, et al. A compositional look at the human gastrointestinal microbiome and 
immune activation parameters in HIV infected subjects. PLoS Pathog. 2014; 10:e1003829. • The 
authors find that HIV infection results in decreased diversity of bacterial communities in the 
colon and ileum. [PubMed: 24586144] 
47. McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P, Braun J. HIV Infection is 
associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome. 
2013; 1:1–12. [PubMed: 24467924] 
48. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, 
Bruls T, Batto JM, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473:174–180. 
[PubMed: 21508958] 
Zevin et al. Page 10













49. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, Krajmalnik-Brown R. Reduced 
incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS 
One. 2013; 8:e68322. [PubMed: 23844187] 
50. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, 
Pamer EG, Abramson SB, et al. Expansion of intestinal Prevotella copri correlates with enhanced 
susceptibility to arthritis. Elife. 2013; 2:e01202. [PubMed: 24192039] 
51. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev 
Gastroenterol Hepatol. 2011; 8:523–531. [PubMed: 21844910] 
52. Schippa S, Conte MP. Dysbiotic events in gut microbiota: impact on human health. Nutrients. 
2014; 6:5786–5805. [PubMed: 25514560] 
53. Dillon SM, Lee EJ, Kotter CV, Austin GL, Gianella S, Siewe B, Smith DM, Landay AL, 
McManus MC, Robertson CE, et al. Gut dendritic cell activation links an altered colonic 
microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal 
Immunol. 2015; 7:983–994. [PubMed: 24399150] 
54. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, Ben Amor K, van Schaik J, 
Vriesema A, Knol J, et al. Early impairment of gut function and gut flora supporting a role for 
alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin 
Microbiol. 2008; 46:757–758. [PubMed: 18094140] 
55. Eschbach M, Schreiber K, Trunk K, Buer J, Jahn D, Schobert M. Long-term anaerobic survival of 
the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J Bacteriol. 2004; 
186:4596–4604. [PubMed: 15231792] 
56. de Bentzmann S, Plesiat P. The Pseudomonas aeruginosa opportunistic pathogen and human 
infections. Environ Microbiol. 2011; 13:1655–1665. [PubMed: 21450006] 
57. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev 
Microbiol. 2011; 9:265–278. [PubMed: 21407243] 
58. Rey FE, Gonzalez MD, Cheng J, Wu M, Ahern PP, Gordon JI. Metabolic niche of a prominent 
sulfate-reducing human gut bacterium. Proc Natl Acad Sci. 2013; 110:13582–13587. [PubMed: 
23898195] 
59. Peleg AY, de Breij A, Adams MD, Cerqueira GM, Mocali S, Galardini M, Nibbering PH, Earl 
AM, Ward DV, Paterson DL, et al. The success of acinetobacter species; genetic, metabolic and 
virulence attributes. PLoS One. 2012; 7:e46984. [PubMed: 23144699] 
60. March C, Regueiro V, Llobet E, Moranta D, Morey P, Garmendia J, Bengoechea JA. Dissection of 
host cell signal transduction during Acinetobacter baumannii-triggered inflammatory response. 
PLoS One. 2010; 5:e10033. [PubMed: 20383325] 
61. Walker RI, Caldwell MB, Lee EC, Guerry P, Trust TJ, Ruiz-Palacios GM. Pathophysiology of 
Campylobacter Enteritis. Microbiological Reviews. 1986; 50:81–94. [PubMed: 3515146] 
62. Bereswill S, Fischer A, Plickert R, Haag LM, Otto B, Kuhl AA, Dasti JI, Zautner AE, Munoz M, 
Loddenkemper C, et al. Novel murine infection models provide deep insights into the “menage a 
trois” of Campylobacter jejuni, microbiota and host innate immunity. PLoS One. 2011; 6:e20953. 
[PubMed: 21698299] 
63. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. Polysaccharide utilization by gut bacteria: 
potential for new insights from genomic analysis. Nat Rev Microbiol. 2008; 6:121–131. [PubMed: 
18180751] 
64. Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, 
Florin TH. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro 
utilization of mucin by other bacteria. Am J Gastroenterol. 2010; 105:2420–2428. [PubMed: 
20648002] 
65. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut 
microbiota metabolic interactions. Science. 2012; 336:1262–1267. [PubMed: 22674330] 
66. Dillon SM, Manuzak JA, Leone AK, Lee EJ, Rogers LM, McCarter MD, Wilson CC. HIV-1 
infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to 
commensal Escherichia coli. J Immunol. 2012; 189:885–896. [PubMed: 22689879] 
67. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal 
inflammatory disease. Nature. 2008; 453:620–625. [PubMed: 18509436] 
Zevin et al. Page 11













68. Troy EB, Kasper DL. Beneficial effects of Bacteroides fragilis polysaccharides on the immune 
system. Front Biosci. 2010; 15:25–34.
69*. Perez-Santiago J, Gianella S, Massanella M, Spina CA, Karris MY, Var SR, Patel D, Jordan PS, 
Young JA, Little SJ, et al. Gut Lactobacillales are associated with higher CD4 and less microbial 
translocation during HIV infection. AIDS. 2013; 27:1921–1931. • The authors find that levels of 
Lactobacillales in anal swabs of HIV-infected individuals associated with decreased microbial 
translocation, higher CD4+ T cell levels and decreased viral load prior to ART. [PubMed: 
24180001] 
70. Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, Quinones M, Deming 
CB, Perkins M, Hazuda DJ, et al. Probiotic/prebiotic supplementation of antiretrovirals improves 
gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013
71. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin 
suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013; 24:160–168. 
[PubMed: 22940212] 
72. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria 
from the human large intestine. FEMS Microbiol Lett. 2009; 294:1–8. [PubMed: 19222573] 
73. Rey FE, Faith JJ, Bain J, Muehlbauer MJ, Stevens RD, Newgard CB, Gordon JI. Dissecting the in 
vivo metabolic potential of two human gut acetogens. J Biol Chem. 2010; 285:22082–22090. 
[PubMed: 20444704] 
74. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, Bewtra M, Knights D, 
Walters WA, Knight R, et al. Linking Long-Term Dietary Patterns with Gut Microbial 
Enterotypes. Science. 2011; 334:105–108. [PubMed: 21885731] 
75. Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE. HIV-induced 
alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. 
Gut Microbes. 2014; 5:562–570. [PubMed: 25078714] 
76**. Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrus ML, Madrid N, Vallejo 
A, Sainz T, Martinez-Botas J, Ferrando-Martinez S, et al. Altered metabolism of gut microbiota 
contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015; 
8:760–772. • The authors characterized the functional gene content after alterations in the 
microbiome in HIV-infected individuals via meta-analysis and found an altered functional profile 
including enrichment of genes associated with LPS biosynthesis, microbial translocation, and 
inflammatory pathways, with loss of genes associated with amino acid metabolisma and energy 
processes. [PubMed: 25407519] 
77. Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and 
inflammatory bowel disease in children. Benef Microbes. 2014:1–9.
78. Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, Ruas-
Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. 
World J Gastroenterol. 2014; 20:15163–15176. [PubMed: 25386066] 
79. Kandasamy S, Chattha KS, Vlasova AN, Rajashekara G, Saif LJ. Lactobacilli and Bifidobacteria 
enhance mucosal B cell responses and differentially modulate systemic antibody responses to an 
oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. Gut Microbes. 2014 0. 
80. Heilpern D, Szilagyi A. Manipulation of intestinal microbial flora for therapeutic benefit in 
inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev 
Recent Clin Trials. 2008; 3:167–184. [PubMed: 18782075] 
81. Murphy EC, Frick IM. Gram-positive anaerobic cocci--commensals and opportunistic pathogens. 
FEMS Microbiol Rev. 2013; 37:520–553. [PubMed: 23030831] 
82. Kumar P, Luo Q, Vickers TJ, Sheikh A, Lewis WG, Fleckenstein JM. EatA, an immunogenic 
protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin. Infect Immun. 
2014; 82:500–508. [PubMed: 24478066] 
83. Nava GM, Carbonero F, Croix JA, Greenberg E, Gaskins HR. Abundance and diversity of mucosa-
associated hydrogenotrophic microbes in the healthy human colon. ISME J. 2012; 6:57–70. 
[PubMed: 21753800] 
Zevin et al. Page 12













84. Levitt MD, Furne J, Springfield J, Suarez F, DeMaster E. Detoxification of hydrogen sulfide and 
methanethiol in the cecal mucosa. The Journal of Clinical Investigation. 1999; 104:1107–1114. 
[PubMed: 10525049] 
85. Loubinoux J, Bronowicki JP, Pereira IAC, Mougenel JL, Le Faou AE. Sulfate-reducing bacteria in 
human feces and their association with infammatory bowel diseases. FEMS Microbiol Ecol. 2002; 
40:107–112. [PubMed: 19709217] 
86. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P, Maxfield LF, Kambal 
A, Duan E, et al. Pathogenic simian immunodeficiency virus infection is associated with 
expansion of the enteric virome. Cell. 2012; 151:253–266. [PubMed: 23063120] 
87*. Mukherjee PK, Chandra J, Retuerto M, Sikaroodi M, Brown RE, Jurevic R, Salata RA, Lederman 
MM, Gillevet PM, Ghannoum MA. Oral mycobiome analysis of HIV-infected patients: 
identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog. 2014; 10:e1003996. 
• The authors characterized the fungal mycobiome in HIV infected vs uninfected individuals and 
found that the oral mycobiome was altered after HIV infection, and dominated in both groups by 
Candida species. [PubMed: 24626467] 
88. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley 
DJ, Phair JP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is 
more closely associated with T lymphocyte activation than with plasma virus burden or virus 
chemokine coreceptor usage. J Infect Dis. 1999; 179:859–870. [PubMed: 10068581] 
89. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is 
associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with 
sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003; 187:1534–1543. 
[PubMed: 12721933] 
90. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, 
Aweeka F, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of 
TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010; 2:32ra36.
91. Klatt NR, Estes JD, Sun X, Ortiz AM, Barber JS, Harris LD, Cervasi B, Yokomizo LK, Pan L, 
Vinton CL, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated 
with mucosal damage in SIV infection. Mucosal Immunol. 2012; 5:646–657. [PubMed: 22643849] 
92. Klatt NR, Brenchley JM. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS. 2010; 
5:135–140. [PubMed: 20543590] 
93. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, Scheinberg P, Price DA, 
Hage CA, Kholi LM, et al. Differential Th17 CD4 T-cell depletion in pathogenic and 
nonpathogenic lentiviral infections. Blood. 2008; 112:2826–2835. [PubMed: 18664624] 
94**. Dillon SM, Lee EJ, Kotter CV, Austin GL, Gianella S, Siewe B, Smith DM, Landay AL, 
McManus MC, Robertson CE, et al. Gut dendritic cell activation links an altered colonic 
microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal 
Immunol. 2015 • The authors find that HIV-altered mucosal bacteria increase activation of gut 
dendritic cells which contributes to gut and systemic T cell activation. 
95. Macpherson AJ, Geuking MB, McCoy KD. Homeland security: IgA immunity at the frontiers of 
the body. Trends Immunol. 2012; 33:160–167. [PubMed: 22410243] 
96. Macpherson AJ, Koller Y, McCoy KD. The bilateral responsiveness between intestinal microbes 
and IgA. Trends Immunol. 2015; 36:460–470. [PubMed: 26169256] 
97. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune 
system. Science. 2012; 336:1268–1273. [PubMed: 22674334] 
98**. Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd KE, Stolarchuk C, 
Scearce R, Foulger A, et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B 
cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014; 16:215–226. 
• The authors find that ileum B cell respones are predominantly to Env gp41 during HIV 
infection, but the majority of these antibodies cross react to commensal bacteria. [PubMed: 
25121750] 
99. Seaton KE, Ballweber L, Lan A, Donathan M, Hughes S, Vojtech L, Moody MA, Liao HX, 
Haynes BF, Galloway CG, et al. HIV-1 specific IgA detected in vaginal secretions of HIV 
uninfected women participating in a microbicide trial in Southern Africa are primarily directed 
toward gp120 and gp140 specificities. PLoS One. 2014; 9:e101863. [PubMed: 25054205] 
Zevin et al. Page 13













100. Jee J, Bonnegarde-Bernard A, Duverger A, Iwakura Y, Cormet-Boyaka E, Martin TL, Steiner 
HE, Bachman RC, Boyaka PN. Neutrophils negatively regulate induction of mucosal IgA 
responses after sublingual immunization. Mucosal Immunol. 2015; 8:735–745. [PubMed: 
25563500] 
101. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction 
between probiotics and the host intestinal mucosa. Nat Rev Microbiol. 2012; 10:66–78. 
[PubMed: 22101918] 
102. d'Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone N, De Girolamo G, Bianchi L, 
Bellelli V, Ascoli-Bartoli T, Marcellini S, et al. Probiotics Reduce Inflammation in Antiretroviral 
Treated, HIV-Infected Individuals: Results of the “Probio-HIV” Clinical Trial. PLoS One. 2015; 
10:e0137200. [PubMed: 26376436] 
103. Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, Gonzalez A, Lerma E, Guelar A, Saenz D, 
Sorli L, Montero M, Horcajada JP, et al. Effect of probiotics (Saccharomyces boulardii) on 
microbial translocation and inflammation in HIV-treated patients- a double-blind, randomized, 
placebo-controlled trial. J Acquir Immune Defic Syndr. 2015; 68:256–263. [PubMed: 25469528] 
104. Gori A, Rizzardini G, Van't Land B, Amor KB, van Schaik J, Torti C, Quirino T, Tincati C, 
Bandera A, Knol J, et al. Specific prebiotics modulate gut microbiota and immune activation in 
HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial. Mucosal 
Immunol. 2011; 4:554–563. [PubMed: 21525866] 
105**. Ortiz AM, Klase ZA, DiNapoli SR, Vujkovic-Cvijin I, Carmack K, Perkins MR, Calantone N, 
Vinton CL, Riddick NE, Gallagher J, et al. IL-21 and probiotic therapy improve Th17 
frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. 
Mucosal Immunol. 2015 • Authors find that combination probiotic and IL-21 treatment in SIv-
infected, Art-suppressed macaques decreases microbial translocation and enahnces immunity, 
specifically with increased Th17 cells. 
106*. Kristoff J, Haret-Richter G, Ma D, Ribeiro RM, Xu C, Cornell E, Stock JL, He T, Mobley AD, 
Ross S, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and 
viral replication. J Clin Invest. 2014; 124:2802–2806. • The authors find that blocking microbial 
translocation early in infection with sevelamer improves prognosis of SIV-infected macaques. 
[PubMed: 24837437] 
107*. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs 
RW, Jacobson JM, Landay AL, et al. Sevelamer does not decrease lipopolysaccharide or soluble 
CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and 
oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014; 
210:1549–1554. • The authors find that 8 weeks of sevelamer therapy did not alter microbial 
translcoation, but reduced inflammatory factors such as soluble tissue factor, LDL and oxidized 
LDS cholesterol. [PubMed: 24864123] 
108. Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, 
Garsia R, Boyd MA, et al. Intensification of antiretroviral therapy with raltegravir or addition of 
hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: 
a randomized controlled trial. J Infect Dis. 2011; 204:1532–1540. [PubMed: 21930607] 
109. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, Amara RR. PD-1 
blockade during chronic SIV infection reduces hyperimmune activation and microbial 
translocation in rhesus macaques. J Clin Invest. 2012; 122:1712–1716. [PubMed: 22523065] 
Zevin et al. Page 14














• HIV infection is associated with persistent inflammation caused by translocation 
of microbes and/or microbial products from the GI lumen to the lamina propria 
and circulation; this process remains elevated even with successful antiretroviral 
treatment
• HIV is also associated with bacterial dysbiosis is characterized by reduced 
abundances of beneficial bacteria and increased abundances of potentially 
inflammatory bacteria
• Both bacterial dysbiosis and translocation have been linked to altered immune 
function and/or persistent inflammation, and are likely causative contributors
• Novel therapies to restore gut ecology and function are necessary to reduce 
inflammation and improve prognosis of ART-treated HIV-infected individuals
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Microbial dysbiosis in HIV is characterized by decreased abundances of Bacteroides, 
Lactobacillus, and beneficial Clostridia with increased abundances of Prevotella and 
pathogenic Proteobacteria, increasing T cell and DC activation. Loss of secretory IgA may 
help to explain the outgrowth of pathogenic bacteria. Increased neutrophil and macrophage 
accumulation in the LP, bacterial activity in the mucosa, and other mechanisms destabilize 
the mucosa and GI epithelium, leading to MT and further accumulation of inflammatory 
microbial products and cytokines in circulation. Together, these mechanisms perpetuate an 
inflammatory cycle that leads to chronic immune activation in ART treated HIV-infected 
individuals.
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Table 1
Bacteria altered in HIV infection and potential role on health and disease progression
Bacteria enriched in HIV-infected individuals
Genus Compounds produced Potential Role(s) in HIV
Prevotella [44,45]
(P. copri)
SCFAs Increase activation of myeloid dendritic cells [53*]
Pseudomonas [38,54]
(P. aeruginosa)
Acetate, Lactate, NO2 [55] Potential opportunistic pathogen [56], mucolytic [57]
Desulfovibrio [45]
(D. piger)
H2S [58] Colonic inflammation [58]
Acinetobacter [44**]
(A. baumannii)
LPS, α-ketoglutarate [59] Can recruit neutrophils by induction of IL-8 production* [60]
Campylobacter [46**]
(C. jejuni)
Enterotoxin, Cytotoxin [61] Induces mucosal inflammation [62]
Ruminococcu s[45]
(R. productus)
Soluble oligosaccharides, SCFAS [63] Mucolytic, Proinflammatory [64]
Escherichia [46**]
(E. coli)
Indole derivatives [65] Mucolytic [57], Increase HIV replication [66]
Bacteria depleted in HIV-infected individuals
Bacteroides [44**-46]
(B. fragilis)
PSA, SCFAs Mucolytic [64], Induces IL-10 production, protects against 




Lactate, B, K Vitamins Support health, increase colonic CD4+ T cells [69*,70]
Bifidobacterium [54]
(B. breve)
Lactate, B, K Vitamins [71] Support health
Eubacterium [47]
(E. rectale)
Butyrate, other SCFAs [65,72] Support colonic health
Coprococcus [44**,46**,47]
(C. eutactus)
Butyrate, other SCFAs [72] Support colonic health
Blautia [44**,46**]
(B. hydrogenotrophica)
Acetate [73] Support colonic health
Ruminococcus [46,47]
(R. productus)




Shown in murine models
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